ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at…
ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million…
Read More...
Read More...
